FINANCINGS

Ascentage Pharma Group has raised $72 million from Future Industry Investment Fund, a private equity fund managed by China's State Development & Investment Corporation Fund Management Corp. Ltd.

Ascletis Pharmaceuticals Co. Ltd. received $100 million from a series B financing.

Avidity Biosciences Inc. said it completed a $16 million series B financing round.

Blackthorn Therapeutics Inc. said it closed a $14 million extension of its series A financing.

Braeburn Pharmaceuticals Inc. filed a registration statement with the SEC seeking to raise $150 million from an IPO.

Clovis Oncology Inc. priced an underwritten public offering of 5 million shares of its common stock at $41 each.

Cytori Therapeutics Inc. entered common stock purchase and registration rights agreements with Lincoln Park Capital Fund LLC in which it will have the right to sell LPC up to $20 million worth of shares over a 30-month period.

Digitalis Ventures has launched a new $100 million fund aimed at investing in health solutions.

Eiger BioPharmaceutical Inc. completed a $25 million debt financing transaction with Oxford Finance LLC.

Jounce Therapeutics Inc. filed a registration statement with the SEC seeking to raise $75 million from an IPO.

Neon Therapeutics Inc. completed a $70 million series B financing.

Nerre Therapeutics Ltd. raised $28.2 million in a series B round.

Obseva SA filed a registration statement with the SEC seeking to raise $86 million from an IPO.

Satsuma Pharmaceuticals Inc. said it closed a $12 million series A round.

Scpharmaceuticals Inc. closed a $45.6 million series B investment round.

Versant Ventures closed Versant Venture Capital VI at a hard cap of $400 million.

DEALS

Abcellera Biologics Inc. plans to apply its monoclonal antibody screening platform in a collaboration with Pfizer Inc. to discover function-modulating antibodies against undisclosed membrane protein targets.

Absorption Systems entered into a technology licensing agreement with Pfizer Inc. The core technology is a human cell line engineered to express an individual drug transport protein, designed to test for potential safety issues early in the drug development process.

Ambrx Inc. and Mabspace Biosciences Co. Ltd. said they agreed to collaborate on discovery and development of multiple antibody-drug conjugates in China and around the world for oncology.

Endologic LLC acquired global rights to renzapride from Alizyme plc, with plans to develop the compound for the treatment of gastroparesis.

Five Prime Therapeutics Inc. said Bristol-Myers Squibb Co. exercised its option to extend the research term of its collaboration to discover, develop and commercialize immuno-oncology therapies directed toward targets in three undisclosed immune checkpoint pathways.

Flamel Technologies SA completed its cross-border merger with its wholly owned Dublin-based subsidiary, Avadel Pharmaceuticals plc, with Avadel surviving the merger as the public holding company.

Myokardia Inc. said Sanofi SA has notified the firm that it has elected to continue the global cardiomyopathy research collaboration formed in August 2014.

Pixarbio Corp. disclosed a takeover bid to acquire Invivo Therapeutics Holdings Corp. for $77 million in stock.

Rana Therapeutics Inc. is acquiring the messenger RNA (mRNA) replacement therapy platform developed by units of Shire plc, which took an undisclosed equity stake in Rana.

Tiziana Life Sciences plc acquired an exclusive worldwide license for NI-1201, a fully human anti-interleukin-6 receptor monoclonal antibody, from Novimmune SA.

. . . AND MORE

Acura Pharmaceuticals Inc. is exploring a full range of financing and strategic alternatives, including a possible sale of the company.

An experimental glaucoma drug developed by Inotek Pharmaceuticals Corp. to augment the eye's natural method of reducing intraocular pressure failed to prove itself better than a placebo at all 12 time points of a pivotal phase III study.

BC Platforms said it was selected to participate in the global partnership known as MultipleMS, designed to discover new or improved treatments for multiple sclerosis.

Fortress Biotech Inc. has formed a new subsidiary, Caelum Biosciences Inc., to advance development of CAEL-101 (11-1F4) for the treatment of amyloid light chain amyloidosis.

Marinus Pharmaceuticals Inc. said the FDA granted orphan status to its CNS-selective GABAA modulator, ganaxolone, for the treatment of fragile X syndrome.

Moderna Therapeutics Inc. will join the Human Vaccines Project focused on decoding the human immune system to accelerate the development of vaccines and immunotherapies against infectious diseases and cancer.

Nivalis Therapeutics Inc. said its board initiated a process to explore and review strategic alternatives focused on maximizing stockholder value from its clinical assets and cash resources.